Apogee Therapeutics has now moved out of the “final trading window” stage and into a completed listed-options end state. On Thursday, September 3, 2026, OCC Information Memo 59702 said the AbbVie merger had already been consummated before the open and that both APGE and 2APGE options now settle through OCC’s cash-settlement system against a fixed USD 13,511.00 cash deliverable per contract.
That is the real phase change. On September 2, 2026, the site’s earlier APGE article was still about the halt window, the expected close, and the difference between shareholder consideration and formal options treatment. By September 3, 2026, that last open question had been answered. OCC fixed the listed-options mechanics, advanced all series expiring after September 18, 2026 to September 18, 2026, and set the exercise-by-exception threshold at USD 0.01 in all account types.
For options traders, this is not mainly a new biotech thesis. It is a contract-discipline story. Once a merger target reaches a fixed cash-only deliverable and an accelerated expiration calendar, the practical questions change from “Will the deal close?” to “What does this contract deliver now, when does it expire now, and how should I think about exercise, assignment, and liquidity now?”
This article is for market commentary and options education only. It is not financial advice, investment advice, trading advice, or a recommendation to buy or sell any security or options contract. Options trading involves risk and is not suitable for all investors. Review the site’s risk disclosure.
What changed on September 3, 2026
The official sequence is now concrete.
Apogee disclosed in its September 3, 2026 Form 8-K that Merger Sub merged with and into the company on that date, with Apogee surviving as a wholly owned subsidiary of AbbVie. The same filing says each share outstanding immediately before the effective time, subject to the usual merger exceptions, was converted into the right to receive USD 135.11 per share in cash.
The filing also says Apogee notified Nasdaq of the consummation, asked Nasdaq to keep the stock halted through September 3, 2026, and requested suspension from trading on Friday, September 4, 2026. AbbVie separately said Apogee common stock ceased trading before the market open on September 3, 2026 and described the total equity value at about USD 10.9 billion.
OCC then completed the listed-options side:
| Item | Final listed-options term |
|---|---|
| Covered roots | APGE and 2APGE |
| Cash deliverable per contract | USD 13,511.00 |
| Settlement method | OCC cash-settlement system |
| Expiration treatment | All series after 2026-09-18 advanced to 2026-09-18 |
| Exercise threshold | USD 0.01 in all account types |
| Exercise style | Existing American-style options remain exercisable before expiration |
| Post-exercise settlement timing | Exercised options continue to settle in one business day |
That table is the whole reason this deserves a separate article phase. The earlier September 2 piece had to stay conservative because the final options memo was not yet confirmed. This new phase is different because the end-state contract terms are no longer hypothetical.
If you want the immediate predecessor phase first, the site already covered APGE’s final trading window and halt timing. For the earlier signed-deal phase, see AbbVie’s definitive cash deal for Apogee.
Why This Matters For Options Traders
The useful lesson is operational, not directional.
1. The stock story is basically over, but the contract story is not
Before a cash merger closes, traders still spend time on spread risk, closing odds, timetable risk, and whether the stock might trade away from the headline value if something breaks. After the close, that open-ended stock narrative matters much less for listed options.
Now the contract is tied to a fixed cash amount. That does not mean every position becomes trivial. It means the task shifts from making a fresh view on Apogee’s stand-alone science to understanding a fixed deliverable and a shortened expiration calendar.
That distinction matters because traders can easily keep using the wrong mental model. Once OCC has published the final cash-only terms, older heuristics built around the stock’s prior trading range are much less useful than the memo itself.
2. Later-dated optionality has been cut back hard
This is one of the most important practical lines in the memo. OCC said all series of Apogee Therapeutics options whose expiration dates are after September 18, 2026 will have their expiration dates advanced to September 18, 2026.
That means a trader who thought a later month still carried its original time horizon is now wrong. The contract may still exist, but not on the calendar the trader originally bought or sold.
This is why merger end-state memos can change risk faster than the underlying symbol suggests. Time value does not just “fade.” It can be forcibly compressed by the corporate-action treatment itself. Readers who want the mechanics background should review options expiration, assignment, and exercise explained and how options pricing works: intrinsic value vs time value.
3. Cash settlement simplifies the deliverable, not every trading decision
There is a common mistake in end-stage merger coverage: people hear “cash-only deliverable” and assume there is nothing left to manage.
That is too simple. Cash settlement removes the need to deliver or receive stock after exercise, but it does not eliminate exercise handling, assignment handling, broker-specific processing, or confusion around expiration changes. OCC explicitly kept the contracts American-style and said expiring series use a USD 0.01 exercise-by-exception threshold.
In practice, the better question is not “Is this stock still attractive?” The better question is “How does my strike compare with the fixed cash deliverable, what time value is really left, and what happens if the contract is exercised or assigned under the new timetable?”
4. This is a cleaner end-state memo than some adjusted-root cases, but discipline still matters
Some completed merger events produce two different memos for two different roots with different cash amounts. APGE is cleaner than that. OCC memo 59702 applies to both APGE and 2APGE and states one cash deliverable of USD 13,511.00 per contract.
That simplicity is helpful, but not a reason to get casual. The more disciplined response is still to verify the exact root, the accelerated expiration date, and how your broker handles final cash-settlement processing. If you want the general settlement refresher, cash-settled vs physically-settled options explained remains the right baseline.
The practical shift from September 2 to September 3
The easiest way to understand the new article phase is to compare it with what was still unknown one day earlier.
On September 2, 2026, the practical lesson was about a last-session merger target. Nasdaq had given the halt timing. The cash price for shareholders was known. But the conservative line still had to distinguish between shareholder economics and final listed-options terms.
On September 3, 2026, that uncertainty narrowed sharply:
- the
8-Kconfirmed the merger was consummated - AbbVie confirmed completion and said Apogee stock stopped trading before the open
- OCC fixed the final cash deliverable
- OCC advanced all later expirations into September 18
- OCC fixed the automatic-exercise threshold at USD 0.01
That is not just more detail on the same story. It is the point where the options lesson changes from deadline management into end-state contract handling.
What Traders May Misunderstand
“The deal closed, so there is nothing left to think about”
Wrong. There may be less open-ended stock uncertainty, but there is still contract-handling risk. Fixed cash deliverables, accelerated expirations, and expiring-series processing all still matter.
“My later-dated APGE contracts still have their original expiration”
Not if they were dated after September 18, 2026. OCC explicitly advanced those later expirations to September 18, 2026.
“Cash settlement removes assignment and exercise issues”
No. Cash settlement changes the deliverable. It does not remove the need to understand exercise-by-exception handling, American-style exercise rights before expiration, or broker-specific operational details. Early assignment risk in options trading is still relevant when the remaining contract life is short and the economics are mostly mechanical.
“This is just yesterday’s APGE article repeated”
It is not. The September 2 article was about the halt window and the expected closing path. The September 3 memo turns the story into a final contract-terms event. That is a different reader lesson.
A balanced way to read the event
The bullish interpretation is narrow. The open question about whether the deal would actually close is now largely gone, which reduces one category of uncertainty that existed earlier in the process.
The bearish interpretation is also narrow. Once a contract becomes cash-only and later expirations are accelerated, the remaining opportunity set can become smaller, more mechanical, and less forgiving than a normal listed equity option setup.
The neutral interpretation is the most useful one. This is not really a fresh debate about Apogee’s pipeline or AbbVie’s acquisition strategy. It is a reminder that once OCC publishes final terms, merger options should be handled as contracts with explicit deliverables and hard dates, not as ordinary stock proxies with a famous ticker.
Bottom line
Apogee’s options story changed materially on Thursday, September 3, 2026 because OCC finished the part that matters most for listed-options handling. APGE and 2APGE now settle against a fixed USD 13,511.00 cash deliverable per contract, later expirations have been pulled into September 18, 2026, and the exercise-by-exception threshold is USD 0.01.
For options traders, that makes this a contract-discipline event, not a new directional edge. Verify the root, verify the accelerated expiration, verify the cash deliverable, and do not assume the old stock narrative still explains the contract you are holding.
This article is not financial advice, investment advice, or trading advice. Options involve substantial risk, including liquidity risk, operational risk, and the risk of misunderstanding corporate-action contract terms.
Sources
- OCC Information Memo 59702, “Apogee Therapeutics, Inc. - Cash Settlement/Acceleration of Expirations Option Symbols: APGE/2APGE”:
https://infomemo.theocc.com/infomemos?number=59702 - Apogee Therapeutics Form 8-K filed September 3, 2026:
https://www.sec.gov/Archives/edgar/data/1974640/000114036126035537/ef20081397_8k.htm - AbbVie press release, “AbbVie Completes Acquisition of Apogee Therapeutics,” September 3, 2026:
https://news.abbvie.com/2026-09-03-AbbVie-Completes-Acquisition-of-Apogee-Therapeutics
